Table 1 Correlation between MYH9 expression and clinicopathological parameters in 168 glioma patients
From: Targeting MYH9 represses USP14-mediated NAP1L1 deubiquitination and cell proliferation in glioma
Characteristics | N | MYH9 expression | P value | |
|---|---|---|---|---|
Low | High | |||
Age (years) | ||||
< 60 | 140 | 73 (43.4%) | 67 (39.9%) | 0.112 |
≥ 60 | 28 | 10 (6.0%) | 18 (10.7%) | |
Gender | ||||
Male | 106 | 51 (30.4%) | 55 (32.7%) | 0.662 |
Female | 62 | 32 (19.0%) | 30 (17.9%) | |
WHO grade | ||||
I-II | 108 | 60 (35.7%) | 48 (28.6%) | 0.032 |
III-IV | 60 | 23 (13.7%) | 37 (22.0%) | |
Recurrence | ||||
No | 76 | 45 (26.8%) | 31 (18.5%) | 0.021 |
Yes | 92 | 38 (22.6%) | 54 (32.1%) | |
Ki-67 index | ||||
< 20% | 87 | 52(31.0%) | 35(20.8%) | 0.005 |
≥ 20% | 81 | 31(18.4%) | 50(29.8%) | |